Small molecule antagonist of CXCR2 and CXCR1 inhibits tumor growth, angiogenesis, and metastasis in pancreatic cancer
Cancer Letters · 2023
DOI: 10.1016/j.canlet.2023.216185 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2023. Verfasst von Dipakkumar R Prajapati und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Microbiology, 985950, Nebraska Medical Center, Omaha, NE, 68198-5900, United States. Hauptthemen laut MEDLINE: Pancreatic Neoplasms. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Pancreatic cancer (PC) has a poor prognosis, and current therapeutic strategies are ineffective in advanced diseases. We and others have shown the aberrant expression of CXCR2 and its ligands in PC development and progression. Our objective for this study was to evaluate the therapeutic utility of CXCR2/1 targeting using an small molecule antagonist, SCH-479833, in different PC preclinical murine models (syngeneic or xenogeneic). Our results demonstrate that CXCR2/1 antagonist had both antitumor and anti-metastatic effects in PC. CXCR2/1 antagonist treatment inhibited tumor cell proliferation, migration, angiogenesis, and recruitment of neutrophils, while it increased apoptosis. Treatment with the antagonist enhanced fibrosis, tumor necrosis, and extramedullary hematopoiesis. Together, these findings suggest that selectively targeting CXCR2/1 with small molecule inhibitors is a promising therapeutic approach for inhibiting PC growth, angiogenesis, and metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Microbiology, 985950, Nebraska Medical Center, Omaha, NE, 68198-5900, United States.
- Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, 68198-5845, United States.
- Department of Pathology and Microbiology, 985950, Nebraska Medical Center, Omaha, NE, 68198-5900, United States. Electronic address: rsingh@unmc.edu.
Förderung
- NCI NIH HHS
Zitieren
APA
Prajapati, D. R., Molczyk, C., Purohit, A., Saxena, S., Sturgeon, R., Dave, B. J., Kumar, S., Batra, S. K., & Singh, R. K. (2023). Small molecule antagonist of CXCR2 and CXCR1 inhibits tumor growth, angiogenesis, and metastasis in pancreatic cancer. Cancer Letters. https://doi.org/10.1016/j.canlet.2023.216185
Vancouver
Prajapati DR, Molczyk C, Purohit A, Saxena S, Sturgeon R, Dave BJ, et al. Small molecule antagonist of CXCR2 and CXCR1 inhibits tumor growth, angiogenesis, and metastasis in pancreatic cancer. Cancer Letters. 2023. doi:10.1016/j.canlet.2023.216185
BibTeX
@article{Prajapati2023,
author = {Prajapati, Dipakkumar R and Molczyk, Caitlin and Purohit, Abhilasha and Saxena, Sugandha and Sturgeon, Reegan and Dave, Bhavana J and Kumar, Sushil and Batra, Surinder K and Singh, Rakesh K},
title = {Small molecule antagonist of CXCR2 and CXCR1 inhibits tumor growth, angiogenesis, and metastasis in pancreatic cancer},
journal = {Cancer Letters},
year = {2023},
doi = {10.1016/j.canlet.2023.216185}
}
EUVIMED